Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

Rhea-AI Summary

Labcorp (NYSE: LH) will release fourth-quarter 2025 financial results before the market opens on Tuesday, February 17, 2026. A conference call and live webcast will begin at 9:00 a.m. ET that day to discuss results, with the earnings release and financial materials posted on the Labcorp Investor Relations website.

Participants may register to receive dial-in numbers and a unique PIN; the webcast and dial-in are listen-only. It is recommended to join 10 minutes before the start. A replay of the webcast will be available about two hours after the live event and remain accessible until February 4, 2027 on the Investor Relations site.

Key Figures

Target enrollment: 20 participants Participant age range: 18–65 years Baseline period: 4 weeks +5 more

8 metrics

Target enrollment 20 participants BREAKTHROUGH Phase 2 basket trial

Participant age range 18–65 years Eligibility criteria for adult subjects

Baseline period 4 weeks Pre-treatment seizure and EEG monitoring

Treatment duration (Absence) 8 weeks BMB-101 treatment phase for Absence Epilepsy group

Treatment duration (DEE) 12 weeks BMB-101 treatment phase for DEE group

Follow-up period 4 weeks Post-treatment safety and effect monitoring

Open-label extension ≥12 months Planned extension for responders to BMB-101

Drug-resistant epilepsy share 30% of epilepsy patients Estimated proportion with drug resistance

Market Reality Check

Price: $284.50 Vol: Volume 1,284,225 is 1.79x...

high vol

$284.50 Last Close

Volume Volume 1,284,225 is 1.79x the 20-day average of 715,855, indicating elevated pre-news activity. high

Technical Trading above the 200-day MA at 258.83, with shares at 262.00 and about 10.8% below the 52-week high.

Peers on Argus

While LH is up 3.16%, key peers are mixed: DGX up 3.47%, NTRA up 1.48%, MTD up 0...

While LH is up 3.16%, key peers are mixed: DGX up 3.47%, NTRA up 1.48%, MTD up 0.38%, WAT down 0.21%, IQV roughly flat at 0.03%. The pattern suggests stock-specific strength rather than a uniform sector move.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	MRD test expansion	Positive	+1.4%	Expanded Plasma Detect MRD portfolio across key solid tumor indications.
Jan 08	Consumer testing access	Positive	+0.4%	Broadened at-home STI PCR test access via Labcorp OnDemand platform.
Jan 08	Asset divestiture	Neutral	+0.4%	NAMSA acquired select Early Development medical device testing assets.
Dec 30	Conference appearance	Neutral	-0.9%	Announced participation in the 44th J.P. Morgan Healthcare Conference.
Dec 02	Lab asset acquisition	Positive	-0.1%	Completed ~$194M acquisition of CHS outreach laboratory assets.

Pattern Detected

Recent operational and testing-related announcements have generally seen modest positive price alignment, with only one slight divergence on an acquisition-led expansion.

Recent Company History

Over the past few months, Labcorp has focused on expanding specialized testing and reshaping its portfolio. On Dec 2, 2025, it completed a $194 million acquisition of outreach lab assets from CHS. In early January 2026, it broadened access to an at-home STI PCR test and expanded its MRD portfolio, with shares rising 0.37% and 1.43% after those updates. Governance and conference participation news around Dec 30, 2025 and late 2025 had limited price impact, framing today’s earnings-date announcement against a backdrop of steady operational execution.

Market Pulse Summary

This announcement sets expectations for Labcorp’s upcoming earnings release, with shares trading abo...

Analysis

This announcement sets expectations for Labcorp’s upcoming earnings release, with shares trading about 10.8% below the 52-week high and above the 200-day MA. Recent news has centered on expanding specialized testing, portfolio reshaping, and steady governance updates, with mostly modest positive price reactions. Investors may focus on how forthcoming results complement these strategic moves, the sustainability of dividend payments like the recent $0.72 declaration, and any updated commentary on growth initiatives.

Key Terms

phase 2, open-label, basket clinical trial, 5-ht2c, +4 more

8 terms

phase 2 medical

"announced the initiation of the BREAKTHROUGH Study, an open-label Phase 2 clinical trial"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

open-label medical

"announced the initiation of the BREAKTHROUGH Study, an open-label Phase 2 clinical trial"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

basket clinical trial medical

"The BREAKTHROUGH study is designed as a basket clinical trial that will include patients"

A basket clinical trial tests a single treatment across multiple patient groups that have different diseases but share a common biological feature, such as the same genetic mutation. Like trying one key in several different locks that use the same cut, it can show whether a drug works broadly or only in specific groups, which matters to investors because positive results can expand the potential market and shorten development time, while negative results can limit expected returns.

5-ht2c medical

"BMB-101 is a novel highly selective 5-HT2C agonist."

A 5-HT2C is a specific protein on cells that responds to the brain chemical serotonin and helps regulate appetite, mood and some metabolic functions. Think of it as a lock that certain drugs can fit into to change how the body signals hunger, emotion or weight; because of that, drugs that activate or block 5-HT2C can create new treatments or carry safety and regulatory risks, making it a key factor for investors assessing pharmaceutical opportunity and uncertainty.

g-protein biased agonism medical

"Its G-protein biased agonism provides an improved mechanism of action for chronic dosing"

G-protein biased agonism describes a drug's ability to activate one cellular signaling route (the G-protein pathway) over another route (such as arrestin), even though both routes are triggered by the same receptor. Think of it like choosing a quieter side road instead of a busy highway to reach the same destination; the drug aims to preserve beneficial effects while reducing unwanted side effects. For investors, this matters because biased drugs can offer improved safety or effectiveness, altering clinical trial success odds, regulatory review, and commercial value.

electroencephalogram (eeg) medical

"generalized spike-wave discharges (GSWD) on 24-hour electroencephalogram (EEG) in participants"

A noninvasive test that records the brain’s electrical activity using small sensors placed on the scalp, producing waveform patterns that reflect how brain cells are firing—think of it as a seismograph for electrical signals in the brain. Investors care because EEGs are widely used to diagnose and monitor neurological conditions, evaluate drug or device effects in clinical trials, and support regulatory and commercial decisions; changes in EEG results can influence trial outcomes, approvals, and market prospects.

generalized spike-wave discharges (gswd) medical

"The primary efficacy endpoints are to evaluate the change in frequency of generalized spike-wave discharges (GSWD)"

Generalized spike-wave discharges are a distinctive pattern of electrical activity seen on a brain-wave recording (EEG), characterized by rapid spikes followed by slower waves occurring across both sides of the brain, often associated with certain types of seizures. Investors should care because these signals are commonly used as objective measures in clinical trials and safety monitoring for neurological drugs and devices, influencing trial outcomes, regulatory decisions and market value much like a clear test score guides product approval.

developmental epileptic encephalopathy (dee) medical

"classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE)."

Developmental epileptic encephalopathy (DEE) is a group of severe, usually early-onset brain disorders where frequent, hard-to-control seizures and abnormal brain activity impair a child’s development and learning — like a house whose wiring repeatedly shorts out and prevents normal function. It matters to investors because DEE defines a clearly identifiable patient population, influences clinical trial design, regulatory risk, pricing and reimbursement decisions, and the potential size and urgency of markets for treatments and diagnostics.

AI-generated analysis. Not financial advice.

BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

The call will be webcast live on the Labcorp Investor Relations website. Participants may also register for the call by clicking on this link, to receive the dial-in numbers and unique PIN to access the call. The webcast and dial-in are listen-only. It is recommended that participants join 10 minutes prior to the start, although participants may register and join at any time during the call.

A replay of the webcast will be available approximately two hours after the conclusion of the live event and will be available until February 4, 2027. To access the webcast recording, visit the Labcorp Investor Relations website.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.

FAQ

When will Labcorp (LH) report fourth-quarter 2025 earnings?

Labcorp will release Q4 2025 results before the market opens on February 17, 2026.

What time is the Labcorp (LH) earnings webcast on February 17, 2026?

The company will host a conference call and live webcast beginning at 9:00 a.m. ET.

How can investors access the Labcorp (LH) Q4 2025 earnings call and materials?

Earnings materials and the live webcast will be posted on the Labcorp Investor Relations website; participants can register to receive dial-in details and a PIN.

Will there be a replay of the Labcorp (LH) February 17, 2026 webcast?

Yes. A replay will be available about two hours after the live event and will remain accessible until February 4, 2027 on the Investor Relations site.

Is the Labcorp (LH) earnings call interactive or listen-only?

The webcast and dial-in are listen-only.